Effectiveness of surgical castration by bilateral subcapsular orchiectomy as monotherapy for the treatment of advanced prostate cancer.
Authors:   Department of Urology, CHU Kara, Kara (Togo), Matchonna Kpatcha Tchilabalo ,   Laboratory of Cancer Research (LaReCa), Kara University (Togo), Gnimdou Botcho ,   Laboratory of Cancer Research (LaReCa), Kara University (Togo),   Department of Urology, CHR Sokodé, Sokodé (Togo), Hola Sikpa Komi ,   Department of Urology, CHU Kara, Kara (Togo),   Laboratory of Cancer Research (LaReCa), Kara University (Togo), Essomendedou Leloua ,   Department of Urology, CHU Sylvanus Olympio, Lomé (Togo), Essodina Padja ,   Department of Urology, CHU Sylvanus Olympio, Lomé (Togo), Viyomé Sewa Edoé ,   Department of Urology, CHU Sylvanus Olympio, Lomé (Togo), Kodjo Tengue ,   Department of Urology, CHU Sylvanus Olympio, Lomé (Togo)
Published: November 2024

Prostate cancer is the most common malignancy in men and the second cause of death due to cancer [1]. Treatment of prostate cancer has been a field of many progresses, but the discovery of the role of androgen in the genesis of prostate cancer by Hugins and Hodges is really a milestone in the treatment of advanced prostate cancer [2]. In patients with advanced prostate cancer, options for androgen ablation include bilateral orchiectomy, therapy with luteinizing hormone-releasing hormone (LHRH) analogues and antagonists, and combined androgen blockade (typically a LHRH analogue plus a first-generation anti-androgen). Although orchiectomy remains the historical gold standard for androgen ablation, LHRH therapy is considered to be equivalent therapeutically. Medical castration has the advantage to induce less psychological effects comparatively to the surgery, reason why in developed countries patients are managed with medical therapy [3]. However, LHRH agonists cannot induce a complete castration levels of testosterone in some patients [4]. Instead, surgical castration can completely eliminate remaining testosterone produced by the Leydig cells in testes [5]. According to the latest recommendations of the European Association of Urology (EAU), androgen deprivation therapy (ADT) is the firstline indication in patients with advanced and metastatic PCa [6]. This first line is made of LHRH agonists, surgical castration representing the second line [7] And Several techniques of surgical castration have been described with comparable results in terms of patient survival and quality of life, but the sub-capsular technique of preserving testicular albuginea and epididymis is the most commonly used [8]. The relatively high cost of chemical castration is a constraint in the therapeutic choice in developing countries [9]. Therefore, surgical castration is an interesting alternative because of its simplicity and affordability in patients, most of whom have no health insurance. In Togo, most patients diagnosed with prostate cancer are at the metastasis stage, and surgical castration is often used as first-line treatment [10]. The aim of this study was to assess the biological and clinical effectiveness of surgical castration as the sole treatment in patients with advanced prostate cancer.